Precision Biosciences Inc.

DTIL

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001357874

E

weakest fifth of 370 graded peers in healthcare

rank 340 of 370; percentile 91.9; sampling error 2.5 points; lower is stronger

A B C D E

E, the bear



Scoreboard

Profitability	E percentile 92.9
Solvency	C percentile 45.5
Growth and financing	D percentile 69.3
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $154.4M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution; fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 12, 2026 224 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$6.71 2026-10-21; market equity $185.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 12, 2026

We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler structure. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 92.9						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

required facts have no common fiscal period end						
Accruals ratio	13.8%	(6.6%)		92.9	809	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 45.5						
Twelve-month failure probability	0.20%	0.07%		69.9	247	2026-06-30
Altman Z double-prime	(7.20)	(0.33)		57.0	754	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31						
Current ratio	13.32x	2.94x		9.6	837	2025-12-31
Growth and financing, sleeve percentile 69.3						
Revenue growth, three-year compound	10.9%	10.1%		47.6	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(13.4%)	2.1%		73.5	703	2025-12-31
Net share issuance, one year	135.9%	2.5%		86.7	634	2026-03-05

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 135.9%
Fortress balance sheet	cash minus debt is 167,353,000 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
335	Q32 Bio Inc. (QTTB)	90.5	E	
336	Dyadic International Inc. (DYAI)	90.8	E	short runway, distress
337	Editas Medicine, Inc. (EDIT)	91.1	E	fortress balance sheet
338	Beyond Air, Inc. (XAIR)	91.3	E	dilution, short runway, distress
339	Century Therapeutics, Inc. (IPSC)	91.6	E	dilution, fortress balance sheet
340	Precision Biosciences Inc. (DTIL)	91.9	E	dilution, fortress balance sheet
341	Airsculpt Technologies, Inc. (AIRS)	92.1	E	late filer
342	Sutro Biopharma, Inc. (STRO)	92.4	E	dilution, short runway, distress, fortress balance sheet
343	Elutia Inc. (ELUT)	92.7	E	short runway, fortress balance sheet
344	China Pharma Holdings, Inc. (CPHI)	93.0	E	dilution, late filer
345	Celularity Inc. (CELU)	93.2	E	short runway, late filer

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-21 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	38.4%	7.7%	70
Distance from 52-week high	(27.7%)	(30.1%)	53
EBIT to enterprise value	(43.0%)	(1.6%)	16
Free cash flow yield	(35.6%)	(1.0%)	17
Book value to price	0.24	0.28	46
Sales to price	0.19	0.31	38
Composite equity issuance, five years	267.6%	20.5%	94
Relative strength against the sector, log excess return	0.11	(0.14)	70

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$86.1M
Operating cash flow, four quarters	-$51.9M
Months of runway	19.9
Days since last periodic filing	77 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$1.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$45.7M	2025-12-31	2026-03-12	10-K	26-017019
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$65.8M	2025-12-31	2026-03-12	10-K	26-017019
3	assets	us-gaap:Assets	$154.4M	2025-12-31	2026-03-12	10-K	26-017019
4	assets	us-gaap:Assets	$136.4M	2024-12-31	2026-03-12	10-K	26-017019
5	current assets	us-gaap:AssetsCurrent	$118.7M	2025-12-31	2026-03-12	10-K	26-017019
6	current liabilities	us-gaap:LiabilitiesCurrent	$8.9M	2025-12-31	2026-03-12	10-K	26-017019
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$528.2M	2025-12-31	2026-03-12	10-K	26-017019
8	operating income	us-gaap:OperatingIncomeLoss	-$52.1M	2025-12-31	2026-03-12	10-K	26-017019
9	book equity	us-gaap:StockholdersEquity	$92.2M	2025-12-31	2026-03-12	10-K	26-017019
10	liabilities	us-gaap:Liabilities	$62.2M	2025-12-31	2026-03-12	10-K	26-017019
11	operating income	us-gaap:OperatingIncomeLoss	-$26.2M	2024-12-31	2026-03-12	10-K	26-017019
12	interest expense	us-gaap:InterestExpense	$1.8M	2024-12-31	2025-03-26	10-K	25-044775
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$34.3M	2025-12-31	2026-03-12	10-K	26-017019
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$68.7M	2024-12-31	2026-03-12	10-K	26-017019
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$48.7M	2023-12-31	2025-03-26	10-K	25-044775
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$25.1M	2022-12-31	2024-03-27	10-K	24-036817
17	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$85,000	2025-12-31	2026-03-12	10-K	26-017019
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$58.4M	2024-12-31	2026-03-12	10-K	26-017019

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$250,000	2024-12-31	2026-03-12	10-K	26-017019
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$84.1M	2023-12-31	2025-03-26	10-K	25-044775
21	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$2.0M	2023-12-31	2025-03-26	10-K	25-044775
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$45.8M	2022-12-31	2024-03-27	10-K	24-036817
23	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$3.3M	2022-12-31	2024-03-27	10-K	24-036817
24	assets	us-gaap:Assets	$159.8M	2023-12-31	2025-03-26	10-K	25-044775
25	assets	us-gaap:Assets	$238.2M	2022-12-31	2024-03-27	10-K	24-036817
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	24,726,695	2026-03-05	2026-03-12	10-K	26-017019
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,481,931	2025-03-20	2025-03-26	10-K	25-044775

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.